Download Files:
A-674563
$60 – $1,050
Products Details
Product Description
– A-674563 is an orally active and selective Akt1 inhibitor with a Ki of 11 nM.
Web ID
– HY-13254
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C22H22N4O
Citations
– Cell Signal. 2023 Jun 9;109:110753.|J Proteome Res. 2018 Oct 5;17(10):3360-3369.|Oncotarget. 2016 May 17;7(20):29131-42. |Aging. 2020 Nov 17;12(22):23114-23128.
References
– [1]Xu L, et al. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells. Biochem Biophys Res Commun. 2016 Apr 15;472(4):662-8.|[2]Wang A, et al. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016 May 17;7(20):29131-42.|[3]Luo Y, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther, 2005, 4(6), 977-986.|[4]Zhu QS, et al. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res, 2008, 68(8), 2895-2903.|[5]Zou Y, et al. Pre-clinical assessment of A-674563 as an anti-melanoma agent. Biochem Biophys Res Commun. 2016 Aug 12;477(1):1-8.
CAS Number
– 552325-73-2
Molecular Weight
– 358.44
Compound Purity
– 99.87
SMILES
– N[C@@H](CC1=CC=CC=C1)COC2=CC(C3=CC4=C(C=C3)NN=C4C)=CN=C2
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 83.33 mg/mL (ultrasonic)
Target
– Akt
Isoform
– Akt1
Pathway
– PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
